Profile data is unavailable for this security.
About the company
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
- Revenue in USD (TTM)80.03m
- Net income in USD-81.45m
- Incorporated2011
- Employees223.00
- LocationPersonalis Inc6600 Dumbarton CircleFREMONT 94555United StatesUSA
- Phone+1 (650) 752-1300
- Fax+1 (302) 531-3150
- Websitehttps://www.personalis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomea Fusion Inc | 0.00 | -139.65m | 315.39m | 112.00 | -- | 3.03 | -- | -- | -3.90 | -3.90 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -72.58 | -- | -80.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 316.58m | 33.00 | -- | 1.37 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
| Sutro Biopharma Inc | 169.36m | -124.45m | 321.30m | 304.00 | -- | 2.11 | -- | 1.90 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Editas Medicine Inc | 67.03m | -193.45m | 322.48m | 265.00 | -- | 1.39 | -- | 4.81 | -2.36 | -2.36 | 0.8183 | 2.81 | 0.1447 | -- | 52.99 | 252,954.70 | -41.75 | -29.85 | -48.49 | -33.19 | -- | -- | -288.59 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -176.00m | 322.49m | 75.00 | -- | 0.6768 | -- | -- | -2.10 | -2.10 | 0.00 | 5.64 | 0.00 | -- | -- | 0.00 | -30.97 | -5.90 | -32.19 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Ocugen Inc | 8.19m | -45.87m | 328.16m | 65.00 | -- | 17.34 | -- | 40.06 | -0.1785 | -0.1785 | 0.0319 | 0.0658 | 0.1265 | -- | -- | 126,015.40 | -78.54 | -83.56 | -103.70 | -97.79 | -- | -- | -620.91 | -2,921.94 | -- | -- | 0.1445 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Design Therapeutics Inc | 0.00 | -50.53m | 331.80m | 57.00 | -- | 1.27 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Personalis Inc | 80.03m | -81.45m | 336.21m | 223.00 | -- | 2.80 | -- | 4.20 | -1.63 | -1.63 | 1.59 | 2.12 | 0.3683 | 6.68 | 6.94 | 358,865.50 | -37.49 | -28.84 | -43.81 | -34.72 | 27.76 | 28.65 | -101.78 | -96.01 | 3.05 | -- | 0.0199 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| MeiraGTx Holdings PLC | 8.12m | -93.14m | 336.52m | 387.00 | -- | 3.52 | -- | 41.43 | -1.49 | -1.49 | 0.1298 | 1.24 | 0.0282 | -- | 0.4733 | 19,384.25 | -32.29 | -26.40 | -40.66 | -32.66 | -- | -- | -1,146.81 | -420.70 | -- | -22.76 | 0.4759 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Lexeo Therapeutics Inc | 0.00 | -77.22m | 344.50m | 58.00 | -- | 2.09 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Voyager Therapeutics Inc | 143.77m | 9.02m | 344.65m | 162.00 | 41.19 | 1.03 | 24.81 | 2.40 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| XOMA Royalty Corp | 15.24m | -25.10m | 349.38m | 13.00 | -- | 3.48 | -- | 22.93 | -2.22 | -2.22 | 1.17 | 8.58 | 0.0826 | -- | 21.36 | 1,172,231.00 | -9.88 | -4.55 | -10.62 | -4.94 | -- | -- | -119.61 | -31.87 | -- | -- | 0.5471 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Poseida Therapeutics Inc | 88.46m | -112.77m | 350.60m | 337.00 | -- | 5.76 | -- | 3.96 | -1.19 | -1.19 | 0.9296 | 0.6265 | 0.3051 | -- | 7.27 | 268,066.70 | -38.89 | -40.70 | -52.75 | -47.72 | -- | -- | -127.48 | -233.49 | -- | -13.14 | 0.4916 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -22.62m | 350.91m | 28.00 | -- | 6.85 | -- | -- | -0.4458 | -0.4458 | 0.00 | 0.8189 | 0.00 | -- | -- | 0.00 | -36.89 | -38.31 | -44.60 | -43.34 | -- | -- | -- | -- | -- | -22.18 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Cartesian Therapeutics Inc | 54.10m | -229.65m | 353.67m | 38.00 | -- | -- | -- | 6.54 | -38.41 | -38.41 | 5.07 | -5.69 | 0.2221 | -- | 2.89 | 1,423,737.00 | -94.26 | -43.66 | -106.38 | -66.84 | -- | -- | -424.47 | -136.35 | -- | -0.3153 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Data as of Sep 20 2024. Currency figures normalised to Personalis Inc's reporting currency: US Dollar USD
36.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 30 Jun 2024 | 6.36m | 11.96% |
| AIGH Capital Management LLCas of 16 Aug 2024 | 4.39m | 8.26% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.89m | 3.56% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.64m | 3.09% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 1.06m | 1.99% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 1.03m | 1.94% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 1.01m | 1.90% |
| Nikko Asset Management Americas, Inc.as of 30 Jun 2024 | 885.42k | 1.66% |
| Jacobs Levy Equity Management, Inc.as of 30 Jun 2024 | 735.01k | 1.38% |
| BlackRock Financial Management, Inc.as of 30 Jun 2024 | 499.31k | 0.94% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
